Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Jazz Pharmaceuticals plc announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. Jazz completed the acquisition of Actio Biosciences through the merger of Knight Acquisition Corp. (the "Merger Sub"), a D…
